BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 10070941)

  • 21. A novel 7-modified camptothecin analog overcomes breast cancer resistance protein-associated resistance in a mitoxantrone-selected colon carcinoma cell line.
    Perego P; De Cesare M; De Isabella P; Carenini N; Beggiolin G; Pezzoni G; Palumbo M; Tartaglia L; Pratesi G; Pisano C; Carminati P; Scheffer GL; Zunino F
    Cancer Res; 2001 Aug; 61(16):6034-7. PubMed ID: 11507048
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic.
    Shiozawa K; Oka M; Soda H; Yoshikawa M; Ikegami Y; Tsurutani J; Nakatomi K; Nakamura Y; Doi S; Kitazaki T; Mizuta Y; Murase K; Yoshida H; Ross DD; Kohno S
    Int J Cancer; 2004 Jan; 108(1):146-51. PubMed ID: 14618629
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Breast cancer resistance protein is localized at the plasma membrane in mitoxantrone- and topotecan-resistant cell lines.
    Scheffer GL; Maliepaard M; Pijnenborg AC; van Gastelen MA; de Jong MC; Schroeijers AB; van der Kolk DM; Allen JD; Ross DD; van der Valk P; Dalton WS; Schellens JH; Scheper RJ
    Cancer Res; 2000 May; 60(10):2589-93. PubMed ID: 10825126
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of efflux transporter ABCG2/BCRP does not restore mitoxantrone sensitivity in irinotecan-selected human leukemia CPT-K5 cells: evidence for multifactorial multidrug resistance.
    Su Y; Lee SH; Sinko PJ
    Eur J Pharm Sci; 2006 Oct; 29(2):102-10. PubMed ID: 16844360
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epithelial cell adhesion molecule promotes breast cancer resistance protein-mediated multidrug resistance in breast cancer by inducing partial epithelial-mesenchymal transition.
    Shi RZ; He YF; Wen J; Niu YN; Gao Y; Liu LH; Zhang XP; Wang Y; Zhang XL; Zhang HF; Chen M; Hu XL
    Cell Biol Int; 2021 Aug; 45(8):1644-1653. PubMed ID: 33760350
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of indomethacin and dexamethasone effects on BCRP-mediated drug resistance in MCF-7 parental and resistant cell lines.
    Elahian F; Kalalinia F; Behravan J
    Drug Chem Toxicol; 2010 Apr; 33(2):113-9. PubMed ID: 20307139
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multidrug resistance in breast cancer cells during epithelial-mesenchymal transition is modulated by breast cancer resistant protein.
    Chen WJ; Wang H; Tang Y; Liu CL; Li HL; Li WT
    Chin J Cancer; 2010 Feb; 29(2):151-7. PubMed ID: 20109342
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Decreased NMIIA heavy chain phosphorylation at S1943 promotes mitoxantrone resistance by upregulating BCRP and N-cadherin expression in breast cancer cells.
    Li K; Li T; Niu Y; Gao Y; Shi Y; He Y; Zhang X; Wang Y; Cao J; Hu X; Chen M; Shi R
    Biochem Cell Biol; 2024 Jun; 102(3):213-225. PubMed ID: 38190650
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Overexpression of wild-type breast cancer resistance protein mediates methotrexate resistance.
    Volk EL; Farley KM; Wu Y; Li F; Robey RW; Schneider E
    Cancer Res; 2002 Sep; 62(17):5035-40. PubMed ID: 12208758
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The multidrug resistance transporter ABCG2 (breast cancer resistance protein 1) effluxes Hoechst 33342 and is overexpressed in hematopoietic stem cells.
    Kim M; Turnquist H; Jackson J; Sgagias M; Yan Y; Gong M; Dean M; Sharp JG; Cowan K
    Clin Cancer Res; 2002 Jan; 8(1):22-8. PubMed ID: 11801536
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of breast cancer resistant protein/mitoxantrone resistance/placenta-specific, ATP-binding cassette transporter as a transporter of NB-506 and J-107088, topoisomerase I inhibitors with an indolocarbazole structure.
    Komatani H; Kotani H; Hara Y; Nakagawa R; Matsumoto M; Arakawa H; Nishimura S
    Cancer Res; 2001 Apr; 61(7):2827-32. PubMed ID: 11306452
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel 5' untranslated region variants of BCRP mRNA are differentially expressed in drug-selected cancer cells and in normal human tissues: implications for drug resistance, tissue-specific expression, and alternative promoter usage.
    Nakanishi T; Bailey-Dell KJ; Hassel BA; Shiozawa K; Sullivan DM; Turner J; Ross DD
    Cancer Res; 2006 May; 66(10):5007-11. PubMed ID: 16707421
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro and in vivo evaluation of WK-X-34, a novel inhibitor of P-glycoprotein and BCRP, using radio imaging techniques.
    Jekerle V; Klinkhammer W; Scollard DA; Breitbach K; Reilly RM; Piquette-Miller M; Wiese M
    Int J Cancer; 2006 Jul; 119(2):414-22. PubMed ID: 16646006
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enhanced expression of human ABC-transporter tap is associated with cellular resistance to mitoxantrone.
    Lage H; Perlitz C; Abele R; Tampé R; Dietel M; Schadendorf D; Sinha P
    FEBS Lett; 2001 Aug; 503(2-3):179-84. PubMed ID: 11513878
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expression and functional analyses of breast cancer resistance protein in lung cancer.
    Kawabata S; Oka M; Soda H; Shiozawa K; Nakatomi K; Tsurutani J; Nakamura Y; Doi S; Kitazaki T; Sugahara K; Yamada Y; Kamihira S; Kohno S
    Clin Cancer Res; 2003 Aug; 9(8):3052-7. PubMed ID: 12912956
    [TBL] [Abstract][Full Text] [Related]  

  • 36. (-)-Epigallocatechin-3-gallate downregulates Pg-P and BCRP in a tamoxifen resistant MCF-7 cell line.
    Farabegoli F; Papi A; Bartolini G; Ostan R; Orlandi M
    Phytomedicine; 2010 Apr; 17(5):356-62. PubMed ID: 20149610
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Folate deprivation induces BCRP (ABCG2) expression and mitoxantrone resistance in Caco-2 cells.
    Lemos C; Kathmann I; Giovannetti E; Dekker H; Scheffer GL; Calhau C; Jansen G; Peters GJ
    Int J Cancer; 2008 Oct; 123(7):1712-20. PubMed ID: 18623116
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Survivin up-regulates the expression of breast cancer resistance protein (BCRP) through attenuating the suppression of p53 on NF-κB expression in MCF-7/5-FU cells.
    Wang QP; Wang Y; Wang XD; Mo XM; Gu J; Lu ZY; Pan ZL; Zhu YX
    Int J Biochem Cell Biol; 2013 Sep; 45(9):2036-44. PubMed ID: 23838170
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reduced intracellular drug accumulation in the absence of P-glycoprotein (mdr1) overexpression in mitoxantrone-resistant human MCF-7 breast cancer cells.
    Nakagawa M; Schneider E; Dixon KH; Horton J; Kelley K; Morrow C; Cowan KH
    Cancer Res; 1992 Nov; 52(22):6175-81. PubMed ID: 1358431
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Drug-resistant proteins in breast cancer: recent progress in multidrug resistance].
    Wu DL; Huang F; Lu HZ
    Ai Zheng; 2003 Apr; 22(4):441-4. PubMed ID: 12704006
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.